{"protocolSection": {"identificationModule": {"nctId": "NCT00767000", "orgStudyIdInfo": {"id": "0941-007"}, "secondaryIdInfos": [{"id": "2008_557"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)", "officialTitle": "A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin"}, "statusModule": {"statusVerifiedDate": "2015-02", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10"}, "primaryCompletionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-10-03", "studyFirstSubmitQcDate": "2008-10-03", "studyFirstPostDateStruct": {"date": "2008-10-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-19", "resultsFirstSubmitQcDate": "2012-07-31", "resultsFirstPostDateStruct": {"date": "2012-09-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-02-02", "lastUpdatePostDateStruct": {"date": "2015-02-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus. The primary hypotheses of this study are that treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be well-tolerated at 1 or more doses that demonstrate efficacy.", "detailedDescription": "This study is a 54-week randomized, double-blind base study with an optional 104-week extension study (MK-0941-007-11). Beginning on Week 16, participants not randomized to the maximum dose of MK-0941 could up-titrate to MK-0941 40 mg three times daily. Participants who complete the 54-week base study are eligible to enter the extension study and will remain in the treatment group to which they were assigned in the base study."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 813, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-0941 10 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0941", "Biological: Lantus", "Drug: Metformin"]}, {"label": "MK-0941 20 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0941", "Biological: Lantus", "Drug: Metformin"]}, {"label": "MK-0941 30 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0941", "Biological: Lantus", "Drug: Metformin"]}, {"label": "MK-0941 40 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0941", "Biological: Lantus", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Comparator: Placebo", "Biological: Lantus", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "MK-0941", "description": "MK-0941 tablets three times daily", "armGroupLabels": ["MK-0941 10 mg", "MK-0941 20 mg", "MK-0941 30 mg", "MK-0941 40 mg"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Matching placebo to MK-0941 three times daily", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Lantus", "description": "Lantus injection once daily", "armGroupLabels": ["MK-0941 10 mg", "MK-0941 20 mg", "MK-0941 30 mg", "MK-0941 40 mg", "Placebo"], "otherNames": ["Insulin glargine injection"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin \u22651500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.", "armGroupLabels": ["MK-0941 10 mg", "MK-0941 20 mg", "MK-0941 30 mg", "MK-0941 40 mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Hemoglobin A1c (HbA1c) Level", "description": "Least square means change from baseline in HbA1c. HbA1c represents the percentage of glycated hemoglobin. A negative number means reduction in HbA1c level.", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event", "timeFrame": "Entire study including 54-week study and 104-week extension"}, {"measure": "Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event", "timeFrame": "Entire study including 54-week study and 104-week extension"}], "secondaryOutcomes": [{"measure": "Change in the Two-hour Post Meal Glucose Level", "description": "Least squares mean change from baseline in 2-hour post meal glucose level.", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158"}, {"measure": "Change in the Fasting Plasma Glucose Level", "description": "Least squares mean change from baseline in fasting plasma glucose.", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158"}, {"measure": "Percentage of Participants Who Achieve an HbA1c of <7.0%", "timeFrame": "Weeks 106 and 158"}, {"measure": "Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%", "timeFrame": "Weeks 54, 106 and 158"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* has type 2 diabetes mellitus\n* has body mass index \\>20 and \\<43 kg/m\\^2\n* is a male, or a female who is unlikely to conceive\n* currently on a stable dose of insulin with or without metformin for Type 2 diabetes mellitus\n\nExtension Study Inclusion Criteria:\n\n* completed the base study either on double-blind study medication or as part of the post-treatment follow up population\n* had \u226585% compliance with double-blind and open-label medication during the base study double-blind treatment period\n\nExclusion Criteria:\n\n* has any history of Type 1 diabetes mellitus or ketoacidosis\n* has received more that 1 week of thiazolidinedione (such as pioglitazone or rosiglitazone) therapy or injectable increatin-based therapy (such as Byetta) within the prior 8 weeks\n* has had \u22652 episodes during their lifetime or \\>1 episode within the past year resulting in hypoglycemic seizures, comas, or unconsciousness\n* is on a weight loss program and is not in the maintenance phase, or patient is taking a weight loss medication (e.g., orlistat, sibutramine, rimonabant) within 8 weeks of Visit 1\n* has undergone surgery within 30 days prior to Visit 1 or has planned major surgery", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21994424", "type": "RESULT", "citation": "Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011 Dec;34(12):2560-6. doi: 10.2337/dc11-1200. Epub 2011 Oct 12."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "FG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "FG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "FG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "FG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "periods": [{"title": "54-week Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "119"}, {"groupId": "FG001", "numSubjects": "117"}, {"groupId": "FG002", "numSubjects": "117"}, {"groupId": "FG003", "comment": "Includes additional participants enrolled to enhance evaluation of the safety profile of MK-0941", "numSubjects": "229"}, {"groupId": "FG004", "comment": "Includes additional participants enrolled to enhance evaluation of the safety profile of MK-0941", "numSubjects": "231"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "108"}, {"groupId": "FG001", "numSubjects": "113"}, {"groupId": "FG002", "numSubjects": "109"}, {"groupId": "FG003", "numSubjects": "225"}, {"groupId": "FG004", "numSubjects": "224"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Creaninine/creatinine clearance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Hyperglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Hypoglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Interruption of study medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Progressive disease", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "13"}]}, {"type": "Study terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "90"}, {"groupId": "FG001", "numSubjects": "102"}, {"groupId": "FG002", "numSubjects": "89"}, {"groupId": "FG003", "numSubjects": "196"}, {"groupId": "FG004", "numSubjects": "194"}]}, {"type": "Reason not reported", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Optional 104-week Extension", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "The extension study was optional. Not all participants completing the 54-week study continued.", "numSubjects": "7"}, {"groupId": "FG001", "comment": "The extension study was optional. Not all participants completing the 54-week study continued.", "numSubjects": "3"}, {"groupId": "FG002", "comment": "The extension study was optional. Not all participants completing the 54-week study continued.", "numSubjects": "7"}, {"groupId": "FG003", "comment": "The extension study was optional. Not all participants completing the 54-week study continued.", "numSubjects": "2"}, {"groupId": "FG004", "comment": "The extension study was optional. Not all participants completing the 54-week study continued.", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Study terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "BG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "BG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "BG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "BG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "117"}, {"groupId": "BG003", "value": "229"}, {"groupId": "BG004", "value": "231"}, {"groupId": "BG005", "value": "813"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "26 to 71 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "117"}, {"groupId": "BG003", "value": "229"}, {"groupId": "BG004", "value": "231"}, {"groupId": "BG005", "value": "813"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "54"}, {"groupId": "BG003", "value": "123"}, {"groupId": "BG004", "value": "115"}, {"groupId": "BG005", "value": "416"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "106"}, {"groupId": "BG004", "value": "116"}, {"groupId": "BG005", "value": "397"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Hemoglobin A1c (HbA1c) Level", "description": "Least square means change from baseline in HbA1c. HbA1c represents the percentage of glycated hemoglobin. A negative number means reduction in HbA1c level.", "populationDescription": "Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent HbA1c", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "117"}, {"groupId": "OG003", "value": "118"}, {"groupId": "OG004", "value": "115"}]}], "classes": [{"title": "Week 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.59", "lowerLimit": "-0.80", "upperLimit": "-0.38"}, {"groupId": "OG001", "value": "-0.72", "lowerLimit": "-0.92", "upperLimit": "-0.52"}, {"groupId": "OG002", "value": "-0.89", "lowerLimit": "-1.10", "upperLimit": "-0.69"}, {"groupId": "OG003", "value": "-0.83", "lowerLimit": "-1.03", "upperLimit": "-0.62"}, {"groupId": "OG004", "value": "-0.08", "lowerLimit": "-0.28", "upperLimit": "0.13"}]}]}, {"title": "Week 54 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 106 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 158 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-0.51", "ciPctValue": "95", "ciLowerLimit": "-0.80", "ciUpperLimit": "-0.22"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-0.64", "ciPctValue": "95", "ciLowerLimit": "-0.93", "ciUpperLimit": "-0.36"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Contrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-0.81", "ciPctValue": "95", "ciLowerLimit": "-1.10", "ciUpperLimit": "-0.53"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-0.75", "ciPctValue": "95", "ciLowerLimit": "-1.04", "ciUpperLimit": "-0.46"}]}, {"type": "SECONDARY", "title": "Change in the Two-hour Post Meal Glucose Level", "description": "Least squares mean change from baseline in 2-hour post meal glucose level.", "populationDescription": "Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "114"}, {"groupId": "OG002", "value": "113"}, {"groupId": "OG003", "value": "115"}, {"groupId": "OG004", "value": "111"}]}], "classes": [{"title": "Week 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "-39.0", "lowerLimit": "-52.0", "upperLimit": "-25.1"}, {"groupId": "OG001", "value": "-29.2", "lowerLimit": "-42.5", "upperLimit": "-15.9"}, {"groupId": "OG002", "value": "-37.4", "lowerLimit": "-51.2", "upperLimit": "-23.6"}, {"groupId": "OG003", "value": "-39.3", "lowerLimit": "-53.1", "upperLimit": "-25.5"}, {"groupId": "OG004", "value": "-2.4", "lowerLimit": "-16.0", "upperLimit": "11.2"}]}]}, {"title": "Week 54 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 106 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 158 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudial model", "paramType": "Least Squares Mean Difference", "paramValue": "-36.6", "ciPctValue": "95", "ciLowerLimit": "-55.6", "ciUpperLimit": "-17.5"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-26.7", "ciPctValue": "95", "ciLowerLimit": "-45.4", "ciUpperLimit": "-8.1"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-35.0", "ciPctValue": "95", "ciLowerLimit": "-54.0", "ciUpperLimit": "-16.0"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-36.9", "ciPctValue": "95", "ciLowerLimit": "-55.9", "ciUpperLimit": "-17.9"}]}, {"type": "SECONDARY", "title": "Change in the Fasting Plasma Glucose Level", "description": "Least squares mean change from baseline in fasting plasma glucose.", "populationDescription": "Full analysis set. The additional participants added to the MK-0941 40 mg and placebo arms to enhance evaluation of safety were not included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Weeks 14, 54, 106, and 158", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "117"}, {"groupId": "OG003", "value": "118"}, {"groupId": "OG004", "value": "115"}]}], "classes": [{"title": "Week 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.0", "lowerLimit": "-19.9", "upperLimit": "0.0"}, {"groupId": "OG001", "value": "-1.5", "lowerLimit": "-10.9", "upperLimit": "7.9"}, {"groupId": "OG002", "value": "-21.1", "lowerLimit": "-30.9", "upperLimit": "-11.2"}, {"groupId": "OG003", "value": "-5.0", "lowerLimit": "-14.9", "upperLimit": "4.8"}, {"groupId": "OG004", "value": "-11.8", "lowerLimit": "-21.4", "upperLimit": "-2.1"}]}]}, {"title": "Week 54 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 106 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}, {"title": "Week 158 (no participants analyzed)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}, {"groupId": "OG004", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 54, 106, or 158"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.791", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "1.8", "ciPctValue": "95", "ciLowerLimit": "-11.6", "ciUpperLimit": "15.2"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.121", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "10.3", "ciPctValue": "95", "ciLowerLimit": "-2.7", "ciUpperLimit": "23.2"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.169", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "-9.3", "ciPctValue": "95", "ciLowerLimit": "-22.6", "ciUpperLimit": "4.0"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Analysis for change from baseline to Week 14", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.321", "statisticalMethod": "Constrained longitudinal model", "paramType": "Least Squares Mean Difference", "paramValue": "6.7", "ciPctValue": "95", "ciLowerLimit": "-6.6", "ciUpperLimit": "20.0"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve an HbA1c of <7.0%", "populationDescription": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158", "reportingStatus": "POSTED", "timeFrame": "Weeks 106 and 158", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%", "populationDescription": "Due to early termination and small numbers of participants, no efficacy analyses were performed at Weeks 106 or 158", "reportingStatus": "POSTED", "timeFrame": "Weeks 54, 106 and 158", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event", "populationDescription": "Full analysis set. Includes additional participants enrolled in the MK-0941 40 mg and placebo groups to enhance evaluation of the safety profile of MK-0941.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Entire study including 54-week study and 104-week extension", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "117"}, {"groupId": "OG003", "value": "229"}, {"groupId": "OG004", "value": "231"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.7"}, {"groupId": "OG001", "value": "79.5"}, {"groupId": "OG002", "value": "80.3"}, {"groupId": "OG003", "value": "65.5"}, {"groupId": "OG004", "value": "65.4"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Entire study including 54-week study and 104-week extension", "groups": [{"id": "OG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin"}, {"id": "OG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "117"}, {"groupId": "OG003", "value": "229"}, {"groupId": "OG004", "value": "231"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.4"}, {"groupId": "OG001", "value": "5.1"}, {"groupId": "OG002", "value": "6.8"}, {"groupId": "OG003", "value": "3.1"}, {"groupId": "OG004", "value": "1.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were collected for the entire study including the 54-week study and 104-week extension", "eventGroups": [{"id": "EG000", "title": "MK-0941 10 mg", "description": "MK-0941 10 mg three times daily plus insulin once daily with or without metformin", "seriousNumAffected": 11, "seriousNumAtRisk": 119, "otherNumAffected": 74, "otherNumAtRisk": 119}, {"id": "EG001", "title": "MK-0941 20 mg", "description": "MK-0941 20 mg three times daily plus insulin once daily with or without metformin", "seriousNumAffected": 12, "seriousNumAtRisk": 117, "otherNumAffected": 75, "otherNumAtRisk": 117}, {"id": "EG002", "title": "MK-0941 30 mg", "description": "MK-0941 30 mg three times daily plus insulin once daily with or without metformin", "seriousNumAffected": 11, "seriousNumAtRisk": 117, "otherNumAffected": 78, "otherNumAtRisk": 117}, {"id": "EG003", "title": "MK-0941 40 mg", "description": "MK-0941 40 mg three times daily plus insulin once daily with or without metformin", "seriousNumAffected": 13, "seriousNumAtRisk": 229, "otherNumAffected": 120, "otherNumAtRisk": 229}, {"id": "EG004", "title": "Placebo", "description": "Placebo three times daily plus insulin once daily with or without metformin", "seriousNumAffected": 8, "seriousNumAtRisk": 231, "otherNumAffected": 101, "otherNumAtRisk": 231}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Macular hole", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Macular oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Retinal haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Cyst rupture", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Hepatic cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Sarcoidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Pelvic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Colon cancer stage 0", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Colon cancer stage I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Hepatic neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Thyroid neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Calculus urinary", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 231}]}, {"term": "Endometrial hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Ovarian mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Arterial haemorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 231}]}], "otherEvents": [{"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 10, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 16, "numAffected": 12, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 22, "numAffected": 17, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 11, "numAffected": 10, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 20, "numAffected": 20, "numAtRisk": 231}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 8, "numAffected": 6, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 231}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 13, "numAffected": 8, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 22, "numAffected": 11, "numAtRisk": 231}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 14, "numAffected": 10, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 10, "numAffected": 8, "numAtRisk": 231}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 12, "numAffected": 12, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 16, "numAffected": 12, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 12, "numAffected": 10, "numAtRisk": 231}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 16, "numAffected": 11, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 14, "numAffected": 11, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 7, "numAffected": 6, "numAtRisk": 231}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 425, "numAffected": 57, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 475, "numAffected": 58, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 719, "numAffected": 57, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 690, "numAffected": 94, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 350, "numAffected": 67, "numAtRisk": 231}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 6, "numAffected": 6, "numAtRisk": 231}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 4, "numAtRisk": 119}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 117}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 117}, {"groupId": "EG003", "numEvents": 16, "numAffected": 13, "numAtRisk": 229}, {"groupId": "EG004", "numEvents": 8, "numAffected": 7, "numAtRisk": 231}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Austria", "Brazil", "Chile", "Colombia", "Costa Rica", "Denmark", "Finland", "France", "Germany", "Guatemala", "Hungary", "India", "Israel", "Italy", "Jordan", "Korea, Republic of", "Lebanon", "Malaysia", "Mexico", "New Zealand", "Norway", "Peru", "Philippines", "Russian Federation", "Saudi Arabia", "South Africa", "Sweden", "Taiwan", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M8240", "name": "Exostoses, Multiple Hereditary", "relevance": "LOW"}, {"id": "M20362", "name": "Osteochondromatosis", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC04", "name": "Neoplasms"}, {"abbrev": "BC05", "name": "Musculoskeletal Diseases"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M128948", "name": "Immunoferon", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}